Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation.

BACKGROUND & AIMS Butyrate oxidation is impaired in intestinal mucosa of patients with inflammatory bowel diseases (IBD). Butyrate uptake by colonocytes involves the monocarboxylate transporter (MCT) 1. We aimed to investigate the role of MCT1 in butyrate oxidation deficiency during colonic inflammation. METHODS Colonic tissues were collected from patients with IBD or healthy controls and from rats with dextran sulfate sodium (DSS)-induced colitis. The intestinal epithelial cell line HT-29 was treated with interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha). MCT1 expression was analyzed by real-time reverse-transcription polymerase chain reaction, Western blot, and immunofluorescence. Butyrate uptake and oxidation in HT-29 cells was assessed using [(14)C]-butyrate. The mechanism of MCT1 gene regulation was analyzed by nuclear run-on and reporter gene assays. RESULTS MCT1 messenger RNA (mRNA) and protein levels were markedly decreased in inflamed colonic mucosa of IBD patients and rats. In HT-29 cells, down-regulation of MCT1 mRNA and protein abundance by IFN-gamma and TNF-alpha correlated with a decrease in butyrate uptake and subsequent oxidation. IFN-gamma and TNF-alpha did not affect MCT1 mRNA stability but rather down-regulated gene transcription. We demonstrate that the cytokine response element is located in the proximal -111/+213 core region of the MCT1 promoter. CONCLUSIONS The data suggest that butyrate oxidation deficiency in intestinal inflammation is a consequence of reduction in MCT1-mediated butyrate uptake. This reinforces the proposition that butyrate oxidation deficiency in IBD is not a primary defect.

[1]  L. Augenlicht,et al.  Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. , 1994, Cancer research.

[2]  O. P. Dinnick,et al.  UNSAFE ANÆSTHETIC SUPPLY SYSTEMS , 1975, The Lancet.

[3]  A. Light,et al.  Mucosal enzyme activity for butyrate oxidation; no defect in patients with ulcerative colitis. , 1996, Gut.

[4]  L. Yin,et al.  The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. , 2000, Gastroenterology.

[5]  H. Blottière,et al.  Butyrate metabolism upstream and downstream acetyl-CoA synthesis and growth control of human colon carcinoma cells. , 2000, European journal of biochemistry.

[6]  S. Shirazi-Beechey,et al.  Identification and characterization of a monocarboxylate transporter (MCT1) in pig and human colon: its potential to transport l‐lactate as well as butyrate , 1998, The Journal of physiology.

[7]  F. Mullick,et al.  Presence and Localization of Three Lactic Acid Transporters (MCT1, −2, and −4) in Separated Human Granulocytes, Lymphocytes, and Monocytes , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[8]  B. Aggarwal,et al.  Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  W. Roediger,et al.  THE COLONIC EPITHELIUM IN ULCERATIVE COLITIS: AN ENERGY-DEFICIENCY DISEASE? , 1980, The Lancet.

[10]  W. Roediger.  Utilization of nutrients by isolated epithelial cells of the rat colon. , 1982, Gastroenterology.

[11]  M. Chapman,et al.  In vivo colonic butyrate metabolism and colonic permeability in extensive ulcerative colitis. , 1998, Gastroenterology.

[12]  J. Galmiche,et al.  Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. , 2000, Gut.

[13]  J. Galmiche,et al.  Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression , 2000, Gut.

[14]  M. Zeitz,et al.  Cytokine-dependent transcriptional down-regulation of epithelial sodium channel in ulcerative colitis. , 2004, Gastroenterology.

[15]  S. Shirazi-Beechey,et al.  The human monocarboxylate transporter, MCT1: genomic organization and promoter analysis. , 2002, Biochemical and biophysical research communications.

[16]  S. Shirazi-Beechey,et al.  Substrate‐induced regulation of the human colonic monocarboxylate transporter, MCT1 , 2002, The Journal of physiology.

[17]  V. Mani,et al.  Decreased expression of apical Na+ channels and basolateral Na+, K+‐ATPase in ulcerative colitis , 2004, The Journal of pathology.

[18]  S. Shirazi-Beechey,et al.  The human colonic monocarboxylate transporter Isoform 1: its potential importance to colonic tissue homeostasis. , 2005, Gastroenterology.

[19]  J. Reimund,et al.  Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. , 1996, Gut.

[20]  Sandy D. Westerheide,et al.  The p65 (RelA) Subunit of NF-κB Interacts with the Histone Deacetylase (HDAC) Corepressors HDAC1 and HDAC2 To Negatively Regulate Gene Expression , 2001, Molecular and Cellular Biology.

[21]  P. Mortensen,et al.  Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis. , 1995, Gut.

[22]  N. Price,et al.  The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. , 1999, The Biochemical journal.

[23]  S. Shirazi-Beechey,et al.  Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy , 2002, British Journal of Cancer.

[24]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[25]  T. Layden,et al.  Mechanism(s) of butyrate transport in Caco-2 cells: role of monocarboxylate transporter 1. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[26]  N. Blin,et al.  Tumour necrosis factor α and nuclear factor κB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide , 2003 .

[27]  J. Fitzpatrick,et al.  Mucosal metabolism in ulcerative colitis and crohn's disease , 1998, Diseases of the colon and rectum.

[28]  Boyle,et al.  Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. , 1994, Gut.

[29]  I. Finnie,et al.  Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism. , 1993, Gut.

[30]  S. Krishnan,et al.  Butyrate and glucose metabolism by colonocytes in experimental colitis in mice , 2000, Gut.